Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas.
Brian SchulteNisha MohindraMohammed MilhemSteven AttiaSteven RobinsonVarun MongaAngela C HirbePeter OppeltJohn CharlsonIrene HelenowskiSusan AbbinantiRasima CehicScott OkunoBrian A Van TineMark AgulnikPublished in: British journal of cancer (2021)
In this prospective trial in refractory metastatic or unresectable STS and osteosarcoma, the combination of pazopanib with topotecan did not meet its primary endpoint of progression-free rate at 12 weeks. The combination of pazopanib with topotecan was associated with a high degree of toxicity.
Keyphrases
- phase ii study
- locally advanced
- soft tissue
- squamous cell carcinoma
- metastatic renal cell carcinoma
- rectal cancer
- open label
- radiation therapy
- liver metastases
- small cell lung cancer
- phase iii
- clinical trial
- study protocol
- oxidative stress
- bone mineral density
- randomized controlled trial
- high grade
- placebo controlled
- gestational age